Triptolide inhibits the progression of atherosclerosis in apolipoprotein E−/− mice

Luo,Longfeng; Yang,Tianlun

doi:10.3892/etm.2016.3619

Triptolide inhibits the progression of atherosclerosis in apolipoprotein E−/− mice

Authors:
- Longfeng Luo
- Tianlun Yang
View Affiliations

Affiliations: Department of Cardiovascular Medicine, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: August 24, 2016 https://doi.org/10.3892/etm.2016.3619
Pages: 2307-2313

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis, the major cause of cardiovascular disease, is accompanied by a chronic inflammatory response during the disease. Triptolide (TPL) is an active natural compound that has been demonstrated to possess anti‑inflammatory activities in various cell types. However, the effects of TPL on atherosclerosis have not yet been studied. The goal of the present study was to determine the effects of TPL on apolipoprotein E knock‑out (ApoE‑/‑) mice fed with a high‑fat diet and to analyze the changes in lipid metabolism and inflammatory cytokines to clarify the underlying molecular mechanisms. Firstly, the genotypes of ApoE‑/‑ mice and corresponding wild‑type mice were identified using polymerase chain reaction. The ApoE‑/‑ mice were randomly divided into four groups: ApoE‑/‑ model mice, and ApoE‑/‑ mice treated with 25, 50 or 100 µg/kg TPL every twice day. Wild‑type mice with the same genetic background constituted the fifth group. The mice in each group were given a high‑fat diet from week 8 after birth until week 20. Total cholesterol and total triglyceride levels were determined at 16 and 20 weeks. The results demonstrated that the levels of total cholesterol and total triglyceride in the plasma were highly increased in ApoE‑/‑ mice models, compared with those of wild‑type mice, and the ApoE‑/‑ mice treated with TPL had decreased levels of total cholesterol and total triglyceride in plasma, which exhibited a dose‑dependent reduction as the dose of TPL increased. Moreover, the effects of TPL on the production of inflammatory cytokines in macrophages were determined by ELISA. The results demonstrated that the macrophages from ApoE‑/‑ mice produced high levels of the inflammatory cytokines tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 and IL‑8. However, following treatment with TPL doses of 25, 50 and 100 µg/kg, the cytokine levels were significantly decreased in a dose‑dependent manner. Additionally, proteins associated with lipid metabolism were tested by western blotting. The results showed that the expression of anti‑ATP‑binding cassette transporter A1 in the macrophages of ApoE‑/‑ mice was increased following treatment with TPL. However, the expression levels of LXRα were not markedly changed following treatment of the mice with different doses of TPL. These results suggest that TPL inhibited the progression of atherosclerosis not only by inhibiting the chronic inflammatory response, but also by regulating lipid metabolism, which may provide new insights useful in the clinical therapy of atherosclerosis.

View Figures

View References

1	Watanabe T, Sato K, Itoh F, Iso Y, Nagashima M, Hirano T and Shichiri M: The roles of salusins in atherosclerosis and related cardiovascular diseases. J Am Soc Hypertens. 5:359–365. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zeng Y, Song JX and Shen XC: Herbal remedies supply a novel prospect for the treatment of atherosclerosis: A review of current mechanism studies. Phytother Res. 26:159–167. 2012. View Article : Google Scholar : PubMed/NCBI
3	Suzuki M, Minami A, Nakanishi A, Kobayashi K, Matsuda S, Ogura Y and Kitagishi Y: Atherosclerosis and tumor suppressor molecules (review). Int J Mol Med. 34:934–940. 2014.PubMed/NCBI
4	Hulthe J, Wikstrand J, Mattsson-Hulten L and Fagerberg B: Circulating ICAM-1 (intercellular cell-adhesion molecule 1) is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58 year-old men: The atherosclerosis and insulin resistance (AIR) study. Clin Sci (Lond). 103:123–129. 2002. View Article : Google Scholar : PubMed/NCBI
5	Maranhão RC and Leite AC Jr: Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease. Curr Pharm Des. 21:1196–1204. 2015. View Article : Google Scholar : PubMed/NCBI
6	Shing CM, Fassett RG, Peake JM and Coombes JS: Voluntary exercise decreases atherosclerosis in nephrectomised ApoE knockout mice. PloS One. 10:e01202872015. View Article : Google Scholar : PubMed/NCBI
7	González-Gay MA, González-Juanatey C, Llorca J and Castañeda S: The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis: Comment on ‘Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review’ by Jamnistki etal. Ann Rheum Dis. 73:e272014. View Article : Google Scholar : PubMed/NCBI
8	Hansson GK: Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J. 69:(Suppl). S38–S41. 1993. View Article : Google Scholar : PubMed/NCBI
9	Pizzi J, Silva LR, Moser D and Leite N: Relationship between subclinical atherosclerosis, blood pressure and lipid profile in obese children and adolescents: A systematic review. Arq Bras Endocrinol Metabol. 57:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kreisberg RA and Oberman A: Clinical review 141: Lipids and atherosclerosis: Lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab. 87:423–437. 2002. View Article : Google Scholar : PubMed/NCBI
11	Zhang L and Yang L: Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: A review of the literature. Molecules. 20:335–347. 2014. View Article : Google Scholar : PubMed/NCBI
12	Ross R: Atherosclerosis is an inflammatory disease. Am Heart J. 138:S419–S420. 1999. View Article : Google Scholar : PubMed/NCBI
13	Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
14	Schlag B, Winkler L, Plonné D, Dürer U and Dargel R: Preparation of apoE-free rat low density lipoprotein for catabolic studies. J Lipid Res. 28:1521–1524. 1987.PubMed/NCBI
15	Martinez-Oliván J, Arias-Moreno X, Velazquez-Campoy A, Millet O and Sancho J: LDL receptor/lipoprotein recognition: Endosomal weakening of ApoB and ApoE binding to the convex face of the LR5 repeat. FEBS J. 281:1534–1546. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kostogrys RB, Franczyk-żarów M, Maślak E, Gajda M, Mateuszuk L, Jackson CL and Chłopicki S: Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR⁻/⁻). Atherosclerosis. 223:327–331. 2012. View Article : Google Scholar : PubMed/NCBI
17	Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, Shimada M and Yazaki Y: Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest. 90:2084–2091. 1992. View Article : Google Scholar : PubMed/NCBI
18	Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K, Murase T, Fukazawa C, Takaku F and Yazaki Y: Overexpression of apolipoprotein E in transgenic mice: Marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc Natl Acad Sci USA. 89:1750–1754. 1992. View Article : Google Scholar : PubMed/NCBI
19	Dallongeville J, Lussier-Cacan S and Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: A meta-analysis. J Lipid Res. 33:447–454. 1992.PubMed/NCBI
20	Zhang SH, Reddick RL, Piedrahita JA and Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468–471. 1992. View Article : Google Scholar : PubMed/NCBI
21	Weingärtner O, Ulrich C, Lütjohann D, Ismail K, Schirmer SH, Vanmierlo T, Böhm M and Laufs U: Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE⁻/⁻ mice. Cardiovasc Res. 90:484–492. 2011. View Article : Google Scholar : PubMed/NCBI
22	Sato M, Yamada Y, Matsuoka H, Nakashima S, Kamiya T, Ikeguchi M and Imaizumi K: Dietary pine bark extract reduces atherosclerotic lesion development in male ApoE-deficient mice by lowering the serum cholesterol level. Biosci Biotechnol Biochem. 73:1314–1317. 2009. View Article : Google Scholar : PubMed/NCBI
23	Gopal K, Kumar K, Nandini R, Jahan P and Kumar MJ: High fat diet containing cholesterol induce aortic aneurysm through recruitment and proliferation of circulating agranulocytes in apoE knock out mice model. J Thromb Thrombolysis. 30:154–163. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zou Y, Du H, Yin M, Zhang L, Mao L, Xiao N, Ren G, Zhang C and Pan J: Effects of high dietary fat and cholesterol on expression of PPAR alpha, LXR alpha and their responsive genes in the liver of apoE and LDLR double deficient mice. Mol Cell Biochem. 323:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Zhang L, Duan W, Liu B, Gong P, Ding Y and Wu X: Anti-inflammatory effects of triptolide by inhibiting the NF-κB signalling pathway in LPS-induced acute lung injury in a murine model. Mol Med Rep. 10:447–452. 2014.PubMed/NCBI
26	Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 42:253–265. 2001. View Article : Google Scholar : PubMed/NCBI
27	Calabresi L, Gomaraschi M, Simonelli S, Bernini F and Franceschini G: HDL and atherosclerosis: Insights from inherited HDL disorders. Biochim Biophys Acta. 1851:13–18. 2015. View Article : Google Scholar : PubMed/NCBI
28	Rao X, Zhong J, Maiseyeu A, Gopalakrishnan B, Villamena FA, Chen LC, Harkema JR, Sun Q and Rajagopalan S: CD36-dependent 7-ketocholesterol accumulation in macrophages mediates progression of atherosclerosis in response to chronic air pollution exposure. Circulation Res. 115:770–780. 2014. View Article : Google Scholar : PubMed/NCBI
29	Woollard KJ: Immunological aspects of atherosclerosis. Clinical Sci. 125:221–235. 2013. View Article : Google Scholar
30	Chen JH, Wang CJ, Wang CP, Sheu JY, Lin CL and Lin HH: Hibiscus sabdariffa leaf polyphenolic extract inhibits LDL oxidation and foam cell formation involving up-regulation of LXRalpha/ABCA1 pathway. Food Chem. 141:397–406. 2013. View Article : Google Scholar : PubMed/NCBI
31	Wang W, Lee Y and Lee CH: Review: The physiological and computational approaches for atherosclerosis treatment. Int J Cardiol. 167:1664–1676. 2013. View Article : Google Scholar : PubMed/NCBI
32	Rodondi N, Auer R, de Bosset Sulzer V, Ghali WA and Cornuz J: Atherosclerosis screening by noninvasive imaging for cardiovascular prevention: A systematic review. J Gen Intern Med. 27:220–231. 2012. View Article : Google Scholar : PubMed/NCBI
33	Hartman J and Frishman WH: Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 22:147–151. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ziaei S and Halaby R: Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review. Avicenna J Phytomed. 6:149–164. 2016.PubMed/NCBI
35	Hoeke G, Kooijman S, Boon MR, Rensen PC and Berbee JF: Role of brown fat in lipoprotein metabolism and atherosclerosis. Circ Res. 118:173–182. 2016. View Article : Google Scholar : PubMed/NCBI
36	Smith BW, Miller RJ, Wilund KR, O'Brien WD Jr and Erdman JW Jr: Effects of tomato and soy germ on lipid bioaccumulation and atherosclerosis in ApoE-/- mice. J Food Sci. 80:H1918–1925. 2015. View Article : Google Scholar : PubMed/NCBI
37	Lee HF, Lee TS and Kou YR: Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats. Respir Physiol Neurobiol. 182:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
38	Han R, Rostami-Yazdi M, Gerdes S and Mrowietz U: Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol. 74:424–436. 2012. View Article : Google Scholar : PubMed/NCBI
39	Matta R, Wang X, Ge H, Ray W, Nelin LD and Liu Y: Triptolide induces anti-inflammatory cellular responses. Am J Transl Res. 1:267–282. 2009.PubMed/NCBI